X

You have been redirected to Ipreo's new Knowledge hub!

All the thought leadership you previously accessed on Ipreo Ink now lives in Ipreo Knowledge, which is fully integrated into Ipreo.com. If you have any questions or are experiencing difficulties locating a resource, please reach out to marketing@ipreo.com
This window will close in:
5
Ipreo Early Edition – The Week Ended December 19, 2014

Ipreo Early Edition – The Week Ended December 19, 2014

Ten deals priced last week, raising just $2.9B in proceeds, in what will likely be the last active week for U.S. deals of the year. If the remainder of the year proves to be as silent as expected, Juno Therapeutics ($264.6M), will go down in the books as the final IPO of 2014, bringing the yearly-total to 278 initial debuts, a staggering 53 more than 2013. Even more fitting is that Juno Therapeutics hails from the Healthcare sector, the space that claims both the first IPO of the year (GlycoMimetics, Inc. on January 10) and now potentially the last, bringing an incredible 105 IPOs to the market this year, the highest number from any sector that we have on record since 2001. Elsewhere last week, four marketed follow-ons and two block trade hit the market accounting for more than two-thirds of the proceeds raised. Ally Financial’s $1.3B block pushed the Financials space even further as the leader of secondary offerings this year, luring 168 deals to the market for a total of $39.6B in proceeds. Looking ahead to 2015, there are 52 issuers sitting in the 6-month backlog, hoping to prime the markets for a year as profitable as 2014.

Download PDF